Go to Where the Patients Are

Novirio plans to do clinical trials in China for its hepatitis B treatment. Though developing nations are not generally considered capable of generating quality data, Novirio is betting that close management will yield data it can submit to FDA and leverage in Asia, where most of the patient population resides. It's a move to boost marketability against a competing drug from Glaxo.